Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

PITTSBURGH (CN) — Bashing a Biden-era law that gives Medicare the power to directly negotiate the price of certain high-cost prescription drugs, an attorney for the pharmaceutical giant Novo Nordisk ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against ... have major ramifications for the Medicare drug price negotiation program, a ...

Meanwhile, current GLP-1 offerings like Ozempic and Wegovy are also subject to the next round of Medicare drug pricing negotiations in the U.S. “Considering the recent market challenges, the share ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Novo Nordisk NVO shares have gained 13.9% in the ... CagriSema demonstrated a lower-than-expected reduction in body weight. Last month, Medicare announced that it will not cover costly weight ...

Novo Nordisk had a head start ... and some have refused to cover them. In most cases, Medicare will not pay for the drugs to treat obesity. The Trump administration recently rejected a Biden ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...